May 4th 2024
A retrospective analysis suggested that immune cells play a role in the progression of paroxysmal nocturnal hemoglobinuria (PNH).
Study Identifies Risk Factors for Thrombosis in Patients With AIHA
July 29th 2022This retrospective study and prospective follow-up provide insight into predictors of thrombotic episodes in patients with autoimmune hemolytic anemia (AIHA) and indicators that anticoagulant prophylaxis may be beneficial to certain patients.
Read More
Risk Factors for Hemophilia-Related Bleeding From Prophylaxis Explored in New Study
June 28th 2022Creating and validating effective risk assessment models could help facilitate appropriate prophylaxis for hemophilia, but more research is needed to confirm the prognostic value of various clinical risk factors and biomarkers.
Read More
Unmet Need Remains in iTTP Treatment, but Caplacizumab Could Be Major Step Forward
May 28th 2022A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP).
Read More
Case Study: Caplacizumab May Salvage Refractory Immune TTP Following COVID-19 Vaccine
May 20th 2022While suggesting that the disorder be included in the differential diagnosis of thrombocytopenia following vaccination, the group emphasized that the benefits of global vaccination against the virus outweigh the risk of this rare complication.
Read More